Introduction
============

The Fibroblast Growth Factor 10 (*Fgf10*) gene has been identified in all examined vertebrates ([@B20]). It belongs to the FGF7 subfamily of FGFs (Figure [1A](#F1){ref-type="fig"}) which was generated from a common ancestral gene during the early evolution of vertebrates and shares amino acids sequence similarities and biochemical functions ([@B63]; Figure [1B](#F1){ref-type="fig"}).

![Fibroblast of Growth Factor (FGF) signaling activation and regulation. **(A)** Schematic of FGF subfamilies (see [@B63]). FGF10 belongs to the FGF7 subfamily and is highlighted in blue. **(B)** Comparison of FGF10 gene/protein in human and mouse. The human FGF10 gene has an extra exon; and the protein length in the two species differs by one amino acid. FGF10 is secreted via the canonical ER-Golgi secretory pathway, as demonstrated by the cleavage of the signal peptide, and have two known glycosylation sites (Source: UniProt). **(C)** Known disease-causing mutations on Fgf10 and Fgfr2 genes. The rare developmental disorders Aplasia of Lacrimal and major Salivary Glands (ALSG), Lacrimo-Auricuo-Dentro-Digital (LADD) syndrome, Aperts' Syndrome and Bent Bone Dysplasia Syndrome (BBDS) result from either the loss of key receptor-binding sites on FGF10 or mutations in the receptor kinase (TK) domains or IgII linker regions ([@B90]; [@B59], [@B60]; [@B22], [@B21]; [@B52]; [@B70]; [@B50]). Interestingly, cases of ALSG caused by the R193X mutation also coincide with Chronic Obstructive Pulmonary Disease (COPD) ([@B38]). More recently, chromosomal translocation and duplication events at the loci of the Fgf10 and Fgfr2 genes have been associated with neurological disorders such as developmental delay and autism ([@B10]; [@B89]). The role of single nucleotide polymorphisms and *de novo* point mutations causing oncogenic expression of Fgf10 and Fgfr2 are also becoming clearer, particularly in pancreatic, gastric, and breast cancers ([@B36]; [@B80]; [@B55]; [@B69]; [@B75]; [@B76]; [@B27]; [@B16]). **(D)** FGF10-dependent activation of FGFR intracellular tyrosine residues (Y; insert), adaptor proteins (gray), protein kinases (red), and transcription factors (blue). Insert on the right: each square represents a phosphorylated tyrosine residue (Y); the numbers correspond to phosphorylated Y residues on FGFR2b identified by proteomics; the color blue indicates higher phosphorylation at a given time point upon FGF10 stimulation of epithelial cells; modified from [@B25]. Dashed arrows represent FGF10-specific activation or inhibition of signaling. The lightning bolt represents the activation of signaling cascades. **(E)** Left, FGF10 bound to heparan sulfate proteoglycans (HSPGs) in the ECM does not activate FGFR and intracellular signaling. Right, FGF10 bound to HSPGs and FGFR induces the recruitment of protein adaptors to FGFR and signaling activation (represented by lightning bolts). **(F)** Schematic representation of FGF10 regulation in response to hormones (orange), miRNAs (dark green), WNT and SHH proteins. **(G)** FGF10 induces FGFR2b internalization into early endosomes and sorting to recycling endosomes and plasma membrane. FGF10 has also been found in the nucleus of certain cell types.](fgene-09-00500-g001){#F1}

Fibroblast Growth Factor 10 is a paracrine signaling growth factor of 215 amino acids with a typical signal sequence for secretion and plays an essential role during development and tissue homeostasis in adults ([@B33]). *Fgf10* knockout (KO) mice die at birth with defects in multiple organ development, including the limb, lung, kidney, salivary gland and adipose tissue ([@B58]). *Fgf10* gene mutations have been associated with diseases, such as aplasia of lacrimal and salivary glands (ALSG) ([@B21]) and lacrimo-auriculo-dento-digital (LADD) syndrome ([@B70]); chronic obstructive pulmonary disease ([@B38]) and certain cancer types, including breast ([@B80]; [@B27]), pancreatic ([@B55]), and gastric ([@B76]) cancers (Figure [1C](#F1){ref-type="fig"}).

Fibroblast Growth Factor 10 activates key intracellular signaling pathways in several cell types leading to the modulation of organ branching and cell proliferation, differentiation, and migration during development; wound healing and tissue repair; maintenance of stem cells compartment; and cancer cell invasion and proliferation ([@B33]). Here, we will summarize known FGF10-dependent intracellular signaling pathways and cellular responses, before focusing on how *Fgf10* expression and activity are modulated in different cellular contexts. Mechanisms underlying FGF10-dependent control of signaling specificity will be discussed and novel technologies to study the multiple roles of FGF10 will be introduced.

FGF10-Dependent Regulators of Intracellular Signaling
=====================================================

Early Signaling Players
-----------------------

The paracrine actions of FGF10 secreted by mesenchymal cells are mediated by the activation of epithelial FGF receptors with extracellular, transmembrane, and cytoplasmic tyrosine kinase domains ([@B63]), and by heparan sulfate proteoglycans (HSPGs) in the extracellular matrix (ECM) ([@B65]). There are four Fibroblast Growth Factor receptor *(*Fgfr*)* genes (*Fgfr1, 2, 3, 4*). *Fgfr1--3* are alternatively spliced into "b" and "c" isoforms, which differ in their extracellular domain and ligand binding specificity and which are expressed by epithelial or mesenchymal cells, respectively ([@B63]). FGF10 has been shown to bind and selectively activate FGFR1b and 2b ([@B64]; [@B95]).

Upon FGF10 binding, FGFRs dimerize and several intracellular tyrosine (Y) residues are trans-autophosphorylated. The sequential order of tyrosine residue phosphorylation has been reported for FGFR1 ([@B26]). The catalytic tyrosine Y653 is phosphorylated first, followed by Y583, Y463, Y585, and Y654 phosphorylation, resulting in full receptor activation. Finally, Y677 and Y766 are phosphorylated, allowing the binding of adaptor molecules to the receptor ([@B26]). FGF10-dependent dynamic phosphorylation of FGFR2b intracellular tyrosine residues has been studied in epithelial cells using quantitative mass spectrometry (MS)-based phosphoproteomics ([@B25]; Figure [1D](#F1){ref-type="fig"}, insert). This study showed that FGF10-dependent phosphorylation of Y734 on FGFR2b (or Y730 on FGFR1) specifically induced cell migration ([@B25]). These findings highlight the importance of the sequence surrounding phosphorylated residues on the activated receptor for ligand-dependent activation of downstream signaling pathways.

Fibroblast Growth Factor receptors engage multiple signaling pathways via adaptor proteins (Figure [1D](#F1){ref-type="fig"}). FGF-regulated substrate 2 (FRS2) binds the juxtamembrane domain of FGFRs independently of receptor activation, and is phosphorylated upon ligand binding, enabling the recruitment of other scaffold proteins, such as tyrosine-protein phosphatase non-receptor type 11 (PTPN11/SHP2) and growth factor receptor-bound protein 2 (GRB2) ([@B61]). FRS2, SHP2, and GRB2 are necessary to activate the extracellular regulated kinases (ERK1/2) pathway upon FGF10 stimulation in several examined cell types ([@B29]; [@B61]; [@B82]) and during the growth of prostate xenografts in mice ([@B39]). Furthermore, FGF10 can induce the direct recruitment of the negative ERK1/2 signaling regulator Sprouty2 to FRS2 in lung epithelial cells ([@B78]). Sprouty2 negatively regulates FGF10-dependent trophoblast invasion ([@B54]), otic placode size ([@B44]), and lung branching ([@B96]). GRB2 has been shown to control basal FGFR2 activation ([@B42]) by competing with the binding of 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 (PLCgγ) to FGFR2 ([@B81]). PLCgγ binds to Y769 of FGFR2 (or Y766 on FGFR1) in the presence of FGF10 and is phosphorylated ([@B47]), resulting in activation of protein kinase C (PKC) and calcium release (Figure [1D](#F1){ref-type="fig"}). Finally, the regulatory subunit of phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) p85 which is known to be indirectly recruited to FGFR via the FRS2/GRB2/GAB1 complex ([@B62]), has been shown to bind to phosphorylated Y734 on FGFR2b upon FGF10 stimulation in epithelial breast cancer cells ([@B25]).

These results suggest context-dependent and fine-tuned modulation of downstream signaling pathways upon FGF10 binding to its receptors. FGF10 acts as a canonical FGFR ligand in recruiting the adaptor proteins FRS2, GRB2, or PLCγ to the receptor, but it can also induce the formation of cell type-specific signaling complexes (e.g., centered on p85). Either structural rearrangements of the receptor or the presence of cell type specific co-activators may explain these two different modes of FGF10 signaling initiation.

Kinases: ERK1/2 and PI3K
------------------------

Fibroblast Growth Factor receptors signal through ERK1/2 during development ([@B17]). For instance, FGF10 and ERK1/2 signaling is necessary during duct elongation of submandibular glands ([@B74]), epithelium tooth growth ([@B15]), and determination of vaginal epithelial cell fate in Müllerian duct epithelium ([@B79]). In human diseases, FGF10 is capable of stimulating the growth of endometrial carcinoma cells by activating the ERK1/2 pathway in a paracrine manner ([@B77]) and is involved in the growth of ameloblastoma -- an epithelial benign tumor of the odontogenic apparatus -- partially signaling through ERK1/2 ([@B53]). It has also been suggested that FGF10 has a potential therapeutic use in lung edema, as FGF10 up-regulates Na,K-ATPase activity in alveolar epithelial cells via the ERK1/2 pathway ([@B83]). Finally, the crosstalk between FGF10 and the ERK1/2 pathway has been extensively studied in cell lines, in which either manipulating the Sprouty2/FRS2 complex which controls ERK1/2 activation ([@B78]), or inhibiting upstream activators of ERK1/2, such as MEK, resulted in decreased FGF10-induced cellular responses ([@B77]; [@B83]; [@B25]).

The role of FGF10 in signaling regulation through PI3K and downstream kinases like protein kinase B (AKT) is less clear (Figure [1D](#F1){ref-type="fig"}). The PI3K/AKT pathway is important for FGF10-dependent survival of hepatoblasts during early stages of hepatogenesis ([@B49]) and for lens development ([@B12]). A role for FGF10/FGFR2/PI3K in neuroprotection after cerebral ischemia has also recently been described ([@B13]).

Even though the role of other kinases in FGF10 signaling specification remains to be determined, FGF10 is a versatile growth factor that enables epithelial cell growth and migration via ERK1/2 and controls cell survival via PI3K/AKT signaling during development and in several pathological conditions.

Transcription Factors
---------------------

Fibroblast Growth Factor 10 is known to control cellular outputs through several transcription factors (Figure [1D](#F1){ref-type="fig"}). FGF10 plays crucial roles in adipogenesis by dynamically modulating the expression of members of the CCAAT/enhancer binding protein (C/EBP) and peroxisome proliferator activated receptor (PPAR) families of transcription factors ([@B71]). ELK-1 and c-MYC, but surprisingly not c-FOS, are regulated by FGF10 in endometrial carcinoma ([@B77]). Finally, FGF10 controls the switch between vaginal and uterine epithelial cells fate via runt-related transcription factor 1 (RUNX1) in Müllerian duct epithelium ([@B79]).

As FGF10 activates both ERK1/2 and PI3K all the known transcription factors that depend on these kinases (e.g., ATF2, ELK1, FOS and FOXO, NFkB, CREB, respectively) ([@B92]; [@B46]) should play a role in FGF10-dependent responses. However, it is not the case for ERK1/2-regulated activation of c-FOS ([@B77]), suggesting that transcriptional regulation in response to FGF10/ERK1/2 signaling is complex and requires further investigation.

FGF10 Crosstalk With Other Signaling Pathways
---------------------------------------------

Among several other important players, we will focus on four families of proteins with a context-specific role in FGF10 signaling (Figure [1D](#F1){ref-type="fig"}).

Neurogenic locus notch homolog protein 1 (NOTCH1) is a receptor controlling cell signaling via several ligands and mechanisms ([@B7]). FGF10 activates NOTCH1 signaling during pancreatic development ([@B30]; [@B56]) but inhibits NOTCH1-dependent regulation of the gene *Hes1* in the adult small intestine ([@B2]).

The functions of WNT ligands, which bind to the frizzled family of seven transmembrane receptors ([@B94]), are modulated by FGF10 signaling during stomach ([@B57]) and lung ([@B85]) development. FGF10 also regulates Bone Morphogenetic Protein 4 (BMP4) during lung branching ([@B88]).

The expression of *Sonic hedgehog protein (*SHH*)*, which plays crucial roles during vertebrate development ([@B23]), is enhanced by FGF10 during the development of limb ([@B93]), prostate gland ([@B31]), and stomach ([@B57]).

Thus, FGF10 modulates a great variety of cellular responses during development and in pathological conditions, through both conventional and ligand-specific signaling players.

Modulation of *FGF10* Expression and Activity
=============================================

Besides known transcription factors (e.g., Tbx4/5, Isl1, Etv1/Ewsv1) ([@B11]; [@B91]; [@B14]), *Fgf10* expression and function are regulated by other factors, including HSPGs and soluble molecules (Figure [1E](#F1){ref-type="fig"}).

Heparan sulfate proteoglycans are a family of glycoproteins composed of a variety of heparan sulfate moieties (HS) attached to a core protein which play critical roles during organ branching and morphogenesis ([@B66]). Cleavage of HSPGs during ECM remodeling can release FGF10 from the ECM affecting epithelial cell proliferation and organ development (Figure [1E](#F1){ref-type="fig"}). FGF10 released from HS in the basement membrane increases salivary and lacrimal gland branching morphogenesis ([@B65]; [@B68]), whereas FGF10 binding to FGFR2b regulates the extent of the response to morphogenetics gradients ([@B45]). Furthermore, the HSPG gradient pattern greatly affects FGF10 functions in the developing lung ([@B35]) and during stomach morphogenesis ([@B32]). At a molecular level, FGF10 has a higher affinity for heparan compared to other FGFs ([@B43]) and it has a preference for certain patterns of sulfation and oligosaccharide length ([@B41]). These unique biophysical properties of FGF10 may explain the great variety of FGF10 roles depending on cellular microenvironment, and may form the basis for the therapeutic control of FGF10 activities *in vivo*.

Fibroblast Growth Factor 10 gene expression is regulated by several hormones (Figure [1F](#F1){ref-type="fig"}). In mouse mammary gland 17 beta-estradiol, but not progesterone, increased the expression of *Fgf10*, whereas prolactin significantly induced *Fgf10* gene expression during pregnancy ([@B18]). In ovine uterus, progesterone regulates *Fgf10* gene expression resulting in improved endometrial functions ([@B72]). These findings might be important not only to better refine FGF10 roles during development, but also to improve hormone-dependent cancer therapies. The latter possibility requires further studies to correlate hormones and FGF10 levels in human tumors, such as prostate or breast cancers.

Other important regulators of *Fgf10* gene expression during organ branching are WNT and SHH (Figure [1F](#F1){ref-type="fig"}). For instance, members of the WNT family are crucial for FGF10-dependent signaling in lung and limb morphogenesis ([@B37]; [@B28]; [@B84], [@B86]). SHH inhibits FGF10 localized expression during lung budding ([@B67]). It is worth noticing that FGF10, WNT, and SHH proteins regulate each other through the establishment of feedback loops in different cells and in a spatio-temporal regulated manner during the development of branching organs (see "FGF10 Crosstalk With Other Signaling Pathways" section above and Figure [1D](#F1){ref-type="fig"}), thus confirming the importance of growth factors signaling crosstalk and dynamic regulation in human development and physiology.

Fibroblast Growth Factor 10 expression can also be controlled by micro-RNAs (miRNAs), which are crucial regulators of gene expression ([@B19]; Figure [1F](#F1){ref-type="fig"}). The mir-17 family of miRNAs is important for FGF10/FGFR2b downstream signaling during lung bud morphogenesis ([@B9]) and miR-31 negatively regulates expression of *Fgf10* during hair follicle growth and hair fiber formation ([@B48]). More recently, it has been suggested that the miR-327/FGF10/FGFR2 signaling axis may be a therapeutic target for treatment of obesity and metabolic diseases ([@B24]) and that the crosstalk between miR-145-5p and FGF10 expression regulates vascular smooth muscle cells proliferation and migration ([@B73]).

Although a comprehensive picture of *Fgf10* expression and activity regulation has clearly emerged, a conundrum in FGF10 signaling still remains: how is FGF10 signaling specificity controlled in different cellular contexts? The importance of subcellular localization in modulating specific aspects of FGF10 responses will be discussed in the next section.

Subcellular Localization
------------------------

The FGF10 receptor FGFR2b is internalized via clathrin-coated pits into intracellular vesicles (early endosomes) (Figure [1G](#F1){ref-type="fig"}), and then sorted to recycling endosomes, rather than to canonical late endosomes for degradation ([@B4]; [@B25]). Therefore, once FGFR2b is recycled back to the plasma membrane it may bind its ligands again and activate signaling in a sustained manner ([@B25]). Either the lack of receptor ubiquitination, which is a signal for degradation ([@B4]), or the recruitment of the adaptor proteins p85 and SH3BP4/TTP to phosphorylated FGFR2b ([@B25]) have been suggested as possible mechanisms underlying FGF10-dependent FGFR2b recycling to the plasma membrane. In either case, the sorting route of FGF10-activated receptors affects downstream signaling activation and cellular outputs, by inducing mitogenic responses in keratinocytes ([@B4]) or breast cancer cell migration and mouse embryonic lung branching ([@B25]). It would be interesting to study the endocytic route followed by FGF10 receptors in other cell types and how this affects downstream responses.

As well as in endosomes, FGF10 has been detected in the cytoplasm of cultured prostate stroma cells ([@B43]) and in the nucleus of urothelial cells ([@B3]; Figure [1G](#F1){ref-type="fig"}). These findings suggest that different subcellular localization of FGF10 may underlie the specificity of FGF10 signaling in different cell types. The importance of FGF10 intracellular localization has been confirmed in studies about the molecular mechanisms underlying the LADD and ALSG human syndromes, which are characterized by mutations in the *Fgf10* gene ([@B70]; [@B21]; Figure [1C](#F1){ref-type="fig"}). Mutated FGF10 failed to translocate into the nucleus. This might attenuate FGF10 intracrine functions, possibly explaining the phenotype observed in LADD or ALSG patients ([@B51]).

Understanding how FGF10 regulates signaling specificity in different cell types depending on its subcellular localization and how *Fgf10* expression is modulated during organ morphogenesis and in human physiology may have therapeutic implications for cell- and growth factor-based personalized medicine.

System Biology Approaches to Study FGF10 Signaling Specificity
==============================================================

To improve our global understanding of FGF10 signaling specificity, 'omics approaches might be useful. MS-based quantitative proteomics has become a powerful technology for investigating proteome function, composition, and post-translational modifications (PTMs) ([@B1]). In a typical shotgun proteomic workflow, proteins from tissues or cells are digested followed by peptide separation using liquid chromatography (LC) and peptide identification using tandem mass spectrometry (LC-MS/MS) ([@B1]). To identify, quantify and localize PTMs an enrichment step is introduced at the peptide level given the low stoichiometry of PTMs, such as phosphorylation (Figure [2A](#F2){ref-type="fig"}). In combination with functional assays phosphoproteomics has been successfully employed to study changes in intracellular signaling in tissues or perturbed cells ([@B87]) and one "functional proteomics" study has analyzed global FGF10 signaling in epithelial cells ([@B25]).

![MS-based proteomic analysis of FGF10 signaling specificity. **(A)** Workflow of a typical shotgun proteomic experiment. Samples are lysed and proteins are digested into peptides. Peptides are then either fractionated to reduce sample complexity for the analysis of the whole cellular proteome or enriched for PTMs like phosphorylation using specific antibodies and chromatographic-based methods. Peptides are then separated and analyzed in the mass spectrometer. High resolution full scan and tandem MS/MS spectra are generated. Data are then analyzed by available software and bioinformatics tools before experimental validation of the most interesting hits. **(B)** Workflow of a proteomic experiment aiming at comparing FGFR1b and FGFR2b signaling in response to FGF10 stimulation. Combining phosphorylated peptide enrichment and immunoprecipitation of FGFRs followed by SDS--PAGE separation and protein in-gel digestion may result in the identification of receptor isoform-specific PTMs, protein interactors, and downstream signaling players. **(C)** Workflow of a proteomic experiment aiming at comparing signaling activation in response to different FGFs. Phosphoproteomics followed by mass spectrometry and bioinformatics will allow uncovering ligand-specific signaling cascades. **(D)** Workflow of a proteomic experiment aiming at deciphering subcellular compartment-specific signaling activation upon FGF10 stimulation. Phosphoproteomics is followed by mass spectrometry analysis and bioinformatics.](fgene-09-00500-g002){#F2}

We suggest a few proteomic approaches to study FGF10 signaling specificity in an unbiased manner:

\(1\) Given the lack of available isoform-specific antibodies, FGF10 signaling can be compared in cells or organs expressing exclusively FGFR1b or 2b, using CRISPR-Cas9-based techniques or transgenic mice, by quantitative interactomics combined with phosphoproteomics. This will (a) increase our understanding of the relative contribution of FGFR1b and 2b isoforms to FGF10 response, as the phenotype of the FGFR2b (but not FGFR1b) KO mice resembles that of FGF10 KO mice ([@B63]); (b) dissect which signaling players depend of FGFR1-2 activation in response to FGF10, based on recent data showing receptor-specific activation of SRC in prostate cancer ([@B40]); (c) uncover the potential role of receptor heterodimerization given the reciprocal auto-phosphorylation of FGFR1 and 2 ([@B5]; [@B8]); and (d) allow studying ligand-dependent receptor interactors and PTMs on the receptor (Figure [2B](#F2){ref-type="fig"}).

\(2\) System-level analysis of cellular signaling in response to different ligands for FGFR1-2b based on quantitative phosphoproteomics would reveal whether or not cellular responses are encoded by the identity of the ligand (Figure [2C](#F2){ref-type="fig"}). Two of the FGFR2b ligands, FGF7 and FGF10, are known to induce cell proliferation and lung cyst-like growth or cell migration and lung cell branching, respectively ([@B6]; [@B25]). However, the contribution of FGF1, 3 or 22 -- which also bind to FGFR2b ([@B63]) -- has never been studied in detail. Quantitative phosphoproteomics would allow dissecting ligand-specific activation of intracellular pathways in different cell-types.

\(3\) MS-based organelles proteomics has been recently used to map protein subcellular localization ([@B34]). FGF10 signaling from different sub-cellular compartments might be dissected using a similar approach at a cellular level upon organelle enrichment followed by phosphoproteomics (Figure [2D](#F2){ref-type="fig"}).

Conclusion
==========

Fibroblast Growth Factor 10-dependent responses range from cell proliferation, migration, and invasion, to multi-organ development, cancer or genetic disease progression. Despite the enormous increase in our understanding of FGF10 signaling and regulation, gaps in our knowledge of FGF10 specificity depending on cellular and extracellular environment still exist. Systems biology approaches, including MS-based quantitative proteomics or high-content microscopy (not discussed here due to space limitations) will contribute to a full understanding of FGF10 signaling. Moving toward personalized treatments for human diseases, this knowledge will be fundamental to develop novel therapies. For instance, recombinant FGF10 or antibodies against FGF10 may be developed to modulate FGF10 signaling depending on cellular context.
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